Cardiol Therapeutics Inc. reported on May 29, 2025, the results from its Annual General Meeting of Shareholders held on May 28, 2025. Shareholders voted overwhelmingly in favor of all Management resolutions, including the election of directors. Notably, Dr. Timothy Garnett was elected as a new member of the Board of Directors.
Dr. Garnett brings over 30 years of pharmaceutical industry experience, including two decades as Chief Medical Officer at Eli Lilly and Company. His expertise spans drug development, regulatory approval, and commercial launch, which is critical for Cardiol as it advances its late-stage clinical programs. Guillermo Torre-Amione, Chair of Cardiol Therapeutics, welcomed Dr. Garnett, emphasizing his talent and patient-centered focus.
His appointment comes at an important time for Cardiol, as the company progresses its pivotal Phase III MAVERIC trial of CardiolRx in recurrent pericarditis. The company is also preparing for database lock, analysis, and reporting top-line results from its Phase II ARCHER trial of CardiolRx in acute myocarditis. Michael Willner concluded his service as a Board member but will continue in an advisory capacity.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.